Raichur: Shilpa Medicare Limited, recently announced that its Investigational New Drug (IND), Nor-Ursodeoxycholic Acid ...
Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on ...
Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...
The trials identified no serious adverse effects, and patients tolerated a daily dosage of 1500 mg for 24 weeks.
Non-alcoholic fatty liver disease (NAFLD) affects nearly 19 crore people in India and about a quarter of the world’s ...
The spike in Shilpa Medicare's stock price came after the company announced the approval of its Investigational New Drug (IND ...
A study from Massachusetts General Hospital has found that growth hormone may help improve liver health in people with ...
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCCAmezalpat builds momentum with both ...
In the medical field, terminology not only guides clinical understanding and patient communication but also impacts research, ...
Scientists at Michigan Medicine have made a significant breakthrough in treating nonalcoholic fatty liver disease (NAFLD), a ...
Since symptoms don’t appear until the condition worsens, the only way to detect fatty liver early is through blood tests (LFT ...